Immunotherapy of metastatic disease.
It appears that the cytokines have significant therapeutic potential as an adjunct to established therapeutic regimens. It appears that, as single agents, they will have minimal therapeutic activity. However, in minimal residual disease settings or after debulking regimens by surgery, chemotherapy, or radiotherapy, significantly increased therapeutic activity can be expected by the addition of cytokines to treatment protocols.
D000818:Animals; D007167:Immunotherapy; D007371:Interferon-gamma / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use; D007377:Interleukin-3 / Q000627:therapeutic use; D008546:Melanoma, Experimental / Q000473:pathology* / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis; D011994:Recombinant Proteins / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000627:therapeutic use
D007376:Interleukin-2; D007377:Interleukin-3; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D007371:Interferon-gamma